Observation Stays No Longer Subject to Concurrent Review

STAR—Inotuzumab Ozogamicin (Besponsa) No Longer a Benefit for NP, CNS, or PA Providers

Wednesday, November 7, 2018

Effective for dates of service on or after December 1, 2018, inotuzumab ozogamicin (Besponsa)—procedure code C9028—will no longer be a benefit for services provided by nurse practitioner (NP), clinical nurse specialist (CNS), or physician assistant (PA) providers. 

Send to a Friend

* Required field

Captcha The math problem above is intended to reduce spam.